Abstract Details

Title Improved Motor Function in Children With Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Treated With Eladocagene Exuparvovec (PTC-AADC): Interim Findings From a Phase 1/2 Study

Topic Child Neurology and Developmental Neurology

Presentation(s) Child Neurology and Developmental Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 034

Objective We report interim findings from a study evaluating efficacy and safety of PTC-AADC, a recombinant adeno-associated virus vector containing human cDNA encoding AADC.

Background

AADC deficiency is caused by mutations in the gene encoding the enzyme AADC, resulting in dopamine deficiency and movement disorders. Current treatments fail to restore dopamine levels and improve motor function.

Design/Methods

This is a 2-year interim analysis from a 5-year, phase 1/2, prospective, open-label study in AADC deficiency using bilateral intraputaminal injections of 1.8 × 10¹¹ vg PTC-AADC. Primary efficacy end point was proportion achieving key milestones using Peabody Developmental Motor Scale, Second Edition (PDMS-2) vs historical controls (n=82). Secondary end points included changes in PDMS-2, Alberta Infant Motor Scale (AIMS), and Bayley-III , and body weight. Pharmacodynamic end points included putaminal ¹⁸F-DOPA uptake on PET. Safety end points included treatment-emergent adverse events (TEAEs) and viral shedding. Mean follow-up was 39.9 months.

Results Of 10 patients treated, 1 withdrew at 11 months (influenza B encephalopathy leading to death). Others completed follow-up through year 2. Two years post-treatment, 50% of patients achieved full head control, 33% were able to sit unassisted, and 22% could stand with support. Mean PDMS-2 total score increased significantly from baseline at 24 months. Similar trends were seen with AIMS and Bayley-III total scores. Hypotonia, oculogyric crises, limb dystonia, and stimulus-provoked dystonia decreased. Mean putaminal ¹⁸F-DOPA uptake increased by year 1 through year 2. No viral shedding was detected. All patients experienced ≥1 TEAE (mostly mild or moderate); none were considered definitely treatment related. 27/131 TEAEs were possibly treatment related, including 18 dyskinesia episodes; most resolved within 6 months.

Conclusions Children with AADC deficiency achieved improvements in motor function after intraputaminal PTC-AADC therapy. No new safety signals were identified. These findings support the efficacy and safety of PTC-AADC in AADC deficiency.

Authors/Disclosures
Mark Pykett PRESENTER	Mark Pykett has received personal compensation for serving as an employee of PTC Therapeutics. Mark Pykett has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for PTC Therapeutics. Mark Pykett has received stock or an ownership interest from PTC Therapeutics. Mark Pykett has received personal compensation in the range of $10,000-$49,999 for serving as a Observer with Pharming Group.
Paul Wuh-Liang Hwu	Paul Wuh-Liang Hwu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics Inc.. Paul Wuh-Liang Hwu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC therapeutics. The institution of Paul Wuh-Liang Hwu has received research support from PTC therapeutics.
Yin-Hsiu Chien	Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Avexis/Norvatis. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Yin-Hsiu Chien has received research support from Sanofi Genzyme.
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details